Bank of America Downgrades Sarepta Therapeutics To Neutral

Bank of America downgraded

from Buy to Neutral. The price target for Sarepta Therapeutics has been raised from $20.00 to $28.00. Sarepta Therapeutics shares have dropped 19.39 percent over the past 52 weeks, while the S&P 500 index has surged 12.33 percent in the same period. Sarepta Therapeutics' shares fell 2.82 percent to $25.50 in pre-market trading.